Physician profile
Raynard J Cheung
NPI 1891758843
$10,765.58
in general payments reported to CMS, 2019-2025
35 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $803 · 2021: $730 · 2022: $1,750 · 2023: $1,626 · 2024: $2,055 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,935.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,543.83 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,150.35 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $832.87 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $628.26 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $615.37 | 2019-2025 | |
| Celgene Corporation | $536.58 | 2021-2024 | Zeposia |
| Pfizer INC. | $293.66 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $215.96 | 2019-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $209.72 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $177.27 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $172.58 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $164.33 | 2025 | Rezdiffra |
| Lilly USA, LLC | $161.83 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $151.10 | 2019-2024 | Dificid |
| Genzyme Corporation | $133.68 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $111.78 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $108.23 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $76.98 | 2019-2022 | |
| Ucb, INC. | $61.15 | 2019 | |
| Daiichi Sankyo INC. | $51.61 | 2022-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $47.35 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $41.74 | 2023-2025 | Zenpep |
| Celltrion USA INC. | $40.82 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $37.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $29.20 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $26.70 | 2019 | |
| Echosens North America, INC. | $24.58 | 2021 | |
| W. L. Gore & Associates, INC. | $22.63 | 2022 | |
| Novo Nordisk INC | $17.08 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2024 | Cyltezo |
| Shionogi INC | $13.84 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.34 | 2020 | |
| Intra-Sana Laboratories | $13.22 | 2022 | |
| Evoke Pharma, INC. | $13.13 | 2023 | Gimoti |
| Alfasigma USA, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raynard Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.